Latest Content

Varegacestat reduced the risk of disease progression or death by 84% vs placebo in progressing desmoid tumors.

The FDA has approved the FoundationOne CDx as a companion diagnostic for inavolisib in HR-positive/HER2-negative, PIK3CA-mutated breast cancer.

Experts outline the key multiple myeloma presentations they are anticipating at the 2026 EHA Congress.

New research highlights a promising investigational treatment using ziftomenib in a difficult-to-treat form of acute myeloid leukemia.

HER3-DXd is being evaluated in the ongoing phase 3 HERTHENA-Breast04 trial in locally advanced or metastatic HR-positive, HER2-negative breast cancer.

Atrial fibrillation was associated with real-world cardiovascular and health care resource utilization burden in CLL/SLL.

Dato-DXd led to benefits in terms of TFST, PFS2, and TSST vs chemotherapy in frontline TNBC.

Post-surgery ctDNA status was prognostic for distant recurrence in early TNBC, and the prognostic value of ctDNA status per WGS outperformed pCR status.

Maurie Markman, MD, discusses the clinical utility of HPV vaccination as a strategy to prevent malignant disease.

Sintilimab plus adjuvant capecitabine did not improve 2-year PFS outcomes vs capecitabine alone in NPC with suboptimal response to induction chemotherapy.

Sharon Giordano will receive the Gianni Bonadonna Breast Cancer Award for significant contributions to breast cancer care and research .

First-line asandeutertinib improved intracranial iORR and IPFS vs osimertinib in EGFR-mutated NSCLC with brain metastases.

Selinexor plus ruxolitinib produced higher SVR35 rates than ruxolitinib alone in JAK inhibitor-naive myelofibrosis.